New depression pill shows promise in quick mood lift
NCT ID NCT06267846
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested an experimental drug called NBI-1070770 in 73 adults with major depressive disorder. Participants took the drug or a placebo for 5 days to see if it could quickly improve depression symptoms. The study is already completed, and results will show whether this approach is worth further testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NBI-1070770
What this could lead to
If successful, this could point toward a fast-acting treatment for depression that works within days.
What could go wrong
This is a small, early-phase trial (73 people) testing a short-term effect. The drug may not outperform placebo, and long-term safety and efficacy are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Neurocrine Clinical Site
Little Rock, Arkansas, 72211, United States
-
Neurocrine Clinical Site
Rogers, Arkansas, 72758, United States
-
Neurocrine Clinical Site
Lemon Grove, California, 91945, United States
-
Neurocrine Clinical Site
Long Beach, California, 90806, United States
-
Neurocrine Clinical Site
Hollywood, Florida, 33024, United States
-
Neurocrine Clinical Site
Maitland, Florida, 32751, United States
-
Neurocrine Clinical Site
Decatur, Georgia, 30030, United States
-
Neurocrine Clinical Site
Savannah, Georgia, 31405, United States
-
Neurocrine Clinical Site
Gaithersburg, Maryland, 20877, United States
-
Neurocrine Clinical Site
Dayton, Ohio, 45439, United States
-
Neurocrine Clinical Site
North Canton, Ohio, 44730, United States
-
Neurocrine Clinical Site
Houston, Texas, 77008, United States
-
Neurocrine Clinical Site
Richardson, Texas, 75080, United States